Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

被引：0

作者：

Price, Timothy ^{[1
,2
]}

Kopetz, Scott ^{[3
]}

Grothey, Axel ^{[4
]}

Van Cutsem, Eric ^{[5
]}

Yaeger, Rona ^{[6
]}

Wasan, Harpreet Singh ^{[7
]}

Yoshino, Takayuki ^{[8
]}

Desai, Jayesh ^{[9
]}

Ciardiello, Fortunato ^{[10
]}

Loupakis, Fotios ^{[11
]}

Hong, Yong S. ^{[12
]}

Steeghs, Neeltje ^{[13
]}

Guren, Tormod K. ^{[14
]}

Arkenau, Hendrik-Tobias ^{[15
]}

Garcia-Alfonso, Pilar ^{[16
]}

Chantrill, Lorraine ^{[17
,18
]}

Tebbutt, Niall ^{[19
]}

Strickland, Andrew ^{[20
,21
]}

Karapetis, Chris ^{[22
,23
]}

Murphy, Felicity ^{[24
]}

Gollerkeri, Ashwin ^{[25
,26
]}

Maharry, Kati ^{[25
,26
]}

Christy-Bittel, Janna ^{[25
,26
]}

Tabernero, Josep ^{[27
]}

机构：

[1] Queen Elizabeth Hosp, Med Oncol Unit, Adelaide, SA, Australia

[2] Univ Adelaide, Adelaide, SA, Australia

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] West Canc Ctr, Germantown, TN USA

[5] Katholieke Univ Leuven, Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Imperial Coll Hlth Care Trust, Hammersmith Hosp, London, England

[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[9] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[10] Univ Campania, Naples, Italy

[11] Ist Toscano Tumori, Pisa, Italy

[12] Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea

[13] Netherlands Canc Inst, Amsterdam, Netherlands

[14] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[15] Sarah Cannon Res Inst UK Ltd, London, England

[16] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[17] St Vincents Hosp, Sydney, NSW, Australia

[18] Wollongong Hosp, Illawarra Canc Care Ctr, Wollongong, NSW, Australia

[19] Austin Hlth, Med Oncol, Melbourne, Vic, Australia

[20] Monash Hlth, Melbourne, Vic, Australia

[21] Monash Univ, Melbourne, Vic, Australia

[22] Flinders Med Ctr, Adelaide, SA, Australia

[23] Flinders Univ S Australia, Adelaide, SA, Australia

[24] Mater Hosp, Brisbane, Qld, Australia

[25] Pfizer Inc, Cambridge, MA USA

[26] Pfizer Inc, Boulder, CO USA

[27] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

242

引用

页码：128 / 128

页数：1

共 50 条

[1] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Keir, Christopher Hunt
Pickard, Michael D.
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Keir, Christopher Hunt
Pickard, Michael D.
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[3] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Kyrre Guren, Tormod
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Hunt Keir, Christopher
Pickard, Michael D.
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
Tabernero, J.
Grothey, A.
Van Cutsem, E.
Yaeger, R.
Wasan, H.
Yoshino, T.
Desai, J.
Ciardiello, F.
Loupakis, F.
Hong, Y. Sang
Steeghs, N.
Guren, T. K.
Arkenau, H-T.
Garcia-Alfonso, P.
Gollerkeri, A.
Pickard, M.
Maharry, K.
Christy-Bittel, J. L.
Anderson, L.
Kopetz, S.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 868 - 868
[5] BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs, choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer
Kopetz, S.
Crothey, A.
Van Cutsem, E.
Yaeger, R.
Wasan, H.
Yoshino, T.
Desai, J.
Ciardiello, F.
Gollerkeri, F.
Maharry, K.
Loupakis, F.
Hong, Y.
Steeghs, F.
Guren, T.
Arkenau, H.
Garcia Alfonso, P.
Sandor, V.
Christy-Bittel, J.
Anderson, L.
Tabernero, J.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[6] BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer
Desai, Jayesh
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia Alfonso, Pilar
Price, Timothy
Strickland, Andrew
Tebbutt, Niall
Karapetis, Christos
Chantrill, Lorraine
Murphy, Felicity
Sandor, Victor
Christy-Bittel, Janna
Anderson, Lisa
Tabernero, Josep
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 99 - 99
[7] ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT BINIMETINIB FOR BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: MANAGEMENT OF ADVERSE EVENTS FROM A RANDOMIZED, 3-ARM, PHASE 3 STUDY VS. THE CHOICE OF EITHER IRINOTECAN OR FOLFIRI PLUS CETUXIMAB (BEACON CRC)
Trevino, Tracy
Kopetz, Scott
Grothey, Axel
Yaeger, Rona
Sandor, Victor
Velez, Lydia
[J]. ONCOLOGY NURSING FORUM, 2020, 47 (02)
[8] BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus /- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer Patients
Wasan, Harpreet
Arkenau, Tobias
Braun, Mike
Samuel, Leslie
Graham, Janet
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Yoshino, Takayuki
Desai, Jayesh
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Sandor, Victor
Christy-Bittel, Janna
Anderson, Lisa
Tabernero, Josep
[J]. BRITISH JOURNAL OF CANCER, 2019, 121 : 24 - 24
[9] Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)
Vogel, Arndt
Hegewisch-Becker, Susanna
Prager, Gerald
Folprecht, Gunnar
Stahl, Michael
Kopetz, Scott
Grothey, Axel
van Cutsetn, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Desai, Jayesh
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Y.
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfons, Pilar
Sandor, Victor
Christy-Bittel, Farina
Anderson, Lisa
Tabernero, Josep
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 55 - 55
[10] Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
Wang, Xicheng
Deng, Yanhong
Zhang, Yanqiao
Liu, Tianshu
Yuan, Xianglin
Yang, Jianwei
Zhang, Tao
Zang, Ai-min
Liu, Yu
Huang, Li
Ye, Feng
Zong, Hong
Ba, Yi
Klauck, Isabelle
Vedovato, Jean-Claude
Groc, Melanie
Guo, Angela
Shen, Lin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3559 - LBA3559

← 1 2 3 4 5 →